Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06085833 | ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions(ANGEL) | recruiting | N/A | 2,706 | ARTIDIS AGINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06545045 | Cognitive Rehabilitation Following Breast Cancer Treatment | recruiting | N/A | 50 | University of Missouri-ColumbiaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors |
| terminated |
| Phase 1 |
| 3 |
| SystImmune Inc.INDUSTRY |
| 1 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT07114601 | A Study of LY4257496 in Participants With Cancer (OMNIRAY)(OMNIRAY) | recruiting | Phase 1 | 421 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | recruiting | Phase 3 | 800 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07287098 | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer(preEMBER) | recruiting | Phase 2 | 600 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT07426913 | Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab | recruiting | N/A | 30 | Virginia Commonwealth UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | not yet recruiting | Phase 2 | 750 | The University of The West IndiesOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07614620 | Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer(HYPNO-AJA2) | recruiting | N/A | 70 | Institut BergoniéOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07619365 | Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 60 | Washington University School of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07643831 | Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer | available | — | — | Genentech, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07748377 | Increasing Breast and Colorectal Cancer Screening in the Community | not yet recruiting | N/A | 80 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07770243 | AI-Based Symptom Management for Post-Treatment Breast Cancer Survivors(AIMS-BC) | not yet recruiting | N/A | 36 | Hong Kong Metropolitan UniversityOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832396 | Community Study to Increase Mammogram Screening Among Overdue Women(IMPLEMENT) | enrolling by invitation | N/A | 15,000 | National University Hospital, SingaporeOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833566 | Biopsy-site-marker in Breast Cancer | recruiting | — | 140 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833891 | Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment(SENOCOHORT) | not yet recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07835139 | Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02620852 | Women Informed to Screen Depending on Measures of Risk (Wisdom Study)(WISDOM) | recruiting | N/A | 100,000 | University of California, San FranciscoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03357120 | Circulating Tumor DNA After Neoadjuvant Chemotherapy(ALIENOR) | completed | N/A | 120 | Institut BergoniéOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT04734262 | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)(SPARK) | active not recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05812040 | Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge | completed | N/A | 134 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La RocheINDUSTRY | 29 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06137833 | Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy | completed | N/A | 92 | Pharmanutra S.p.a.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06411678 | Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer | recruiting | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07338721 | Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? | completed | — | 100 | Antalya Training and Research HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07524855 | A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer(HLD-0117) | recruiting | Phase 1 | 170 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829900 | First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer | completed | — | 2,250 | Xin LiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831460 | Horse-assisted Interventions in an Oncological Centre(ISACCO) | completed | N/A | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831889 | Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | not yet recruiting | N/A | 960 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT01334021 | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer | active not recruiting | Phase 2 | 1,100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT02221700 | Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies | active not recruiting | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02455791 | Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery | active not recruiting | N/A | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer(NATALEE) | active not recruiting | Phase 3 | 5,101 | Novartis PharmaceuticalsINDUSTRY | 20 | Sep 18, 2026 | clinicaltrials |
| NCT03796559 | Magseed Enabled Long-Term Localization of Axillary Lymph Nodes(MAGELLAN) | recruiting | N/A | 65 | Endomagnetics Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04090398 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04524000 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | active not recruiting | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04544189 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | active not recruiting | Phase 2 | 69 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | suspended | — | 5,000 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04871139 | An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer | active not recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials